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Statement of findings
The antigenic specificity of an unusual antinuclear antibody pattern in three patient sera was
identified after separating HeLa-cell nuclear extracts by two-dimensional (2D) gel
electrophoresis and localizing the antigens by immunoblotting with patient serum. Protein
spots were excised from the 2D gel and their contents were analyzed by matrix-assisted
laser desorption-ionization (MALDI) or nanoelectrospray ionization time-of-flight (TOF)
tandem mass spectrometry (MS) after in-gel digestion with trypsin. A database search
identified the proteins as the C1 and C2 heterogeneous nuclear ribonucleoproteins. The
clinical spectrum of patients with these autoantibodies includes arthritis, psoriasis, myositis,
and scleroderma. None of 59 patients with rheumatoid arthritis, 19 with polymyositis, 33
with scleroderma, and 10 with psoriatic arthritis had similar antibodies. High-resolution
protein-separation methods and mass-spectrometric peptide mapping in combination with
database searches are powerful tools in the identification of novel autoantigen specificities.
Keywords: antinuclear antibodies, autoantibodies, heterogeneous nuclear ribonucleoproteins C1/C2, mass
spectrometry
Synopsis
1D = one-dimensional; 2D = two-dimensional; ANA = antinuclear antibody; CHAPS = 3-([3-cholamidopropyl]-dimethylammonio)-1-propane
sulfonate; ELISA = enzyme-linked immunoassay; ESI-Q-TOF = electrospray ionization/quadrupole/time-of-flight; hnRNP = heterogeneous nuclear
RNP; HPLC = high-performance liquid chromatography; MALDI-MS = matrix-assisted laser desorption-ionization/mass spectrometry; MALDI-TOF
= matrix-assisted laser desorption-ionization time-of-flight; MS = mass spectrometry; NRDP = non-redundant protein sequence database; 
RNP = ribonucleoprotein; SDS = sodium dodecyl sulfate.
Introduction: The classification of antinuclear antibodies
(ANAs) is important for diagnosis and prognosis and for
understanding the molecular pathology of autoimmune
disease. Many of the proteins that associate with RNA in the
ribonucleoprotein (RNP) complexes of the spliceosome have
been found to react with some types of ANA [1], including
proteins of the heterogeneous nuclear RNP (hnRNP)
complex that associate with newly transcribed pre-mRNA.
Autoantibodies to the A2, B1, and B2 proteins of hnRNP
found in some patients may be markers of several overlap
syndromes [2]. However, ANAs with specificity for these
proteins as well as for the D protein also appear to occur in
many distinct connective-tissue diseases, although epitope
specificities may differ [3]. ANAs with specificity for the C
component of hnRNP (consisting of the C1 and C2 proteins)
have to our knowledge so far been described in only one
case [4]. We here describe the approach taken to
unambiguously identify the C1/C2 proteins as ANA targets
in the sera of some patients.
Aims: To determine the fine specificity of sera containing an
unusual speckled ANA-staining pattern using a combination of
2D gel electrophoresis and MS.
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Introduction
The determination of the molecular and submolecular
specificity of ANAs is important for diagnosis and progno-
sis in clinical medicine and for understanding the molecular
pathology of autoimmune disease. Different antigenic
specificities of ANA are associated with different diseases
and different patterns of disease manifestations. The
various protein antigens associated with ANAs characteris-
tically represent molecules that bind nucleic acids. Thus,
many of the proteins that associate with RNA in the RNP
complexes of the spliceosome have been found to react
with some types of ANA [1]. Also, the hnRNP complex that
associates with newly transcribed pre-mRNA contains pro-
teins that have been shown to be targets of ANAs in some
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Methods: Patient sera were screened for ANAs by indirect
immunofluorescence microscopy on HEp-2 cells (cultured
carcinoma cells). Sera with an unusual, very regular, speckled
ANA pattern were tested for reactivity with components of
nuclear extracts of HeLa cells that were separated by one-
dimensional (1D) or 2D gel electrophoresis or by reversed-phase
high-performance liquid chromatography (HPLC). IgG reactivity
was assessed by immunoblotting. Reactive protein spots from
2D separations were excised from the gels and subjected to in-
gel digestion with trypsin for subsequent peptide mapping,
partial peptide sequencing, and protein identification by MS and
tandem MS on a hybrid electrospray ionization/quadrupole/time-
of-flight (ESI-Q-TOF) mass spectrometer [5–7].
Results: We observed a strong nuclear staining pattern (titer
>1280) with the characteristic even-sized coarse speckles
and no staining of nucleoli in sera from three patients. On
immunoblots of nuclear extracts from HeLa cells, these sera
stained two distinct bands, at Mr 42000 and 41000. The
reactivity strongly resembled that of the patient originally
described by Stanek et al [4]. The antigens were enriched by
fractionating the extract using reversed-phase HPLC on a C4
column, and the two reactive spots on 2D separations were
excised for identification. The two components appeared to
be of approximately the same isoelectric points, although
their molecular masses differed by approximately 2000.
Peptide-mass mapping was performed by matrix-assisted
laser desorption-ionization time-of-flight (MALDI-TOF) MS on
the tryptic peptide mixture generated by digestion of the two
excised proteins. The database search suggested that the
two proteins were C1/C2 hnRNPs (Swissprot accession
number P07910). The identity of the proteins was further
confirmed by tandem MS using an ESI-Q-TOF instrument.
One peptide carrying two positive charges (m/z 580.32 Da),
corresponding to a peptide mass of 1158.7 Da, was selected
as a precursor ion and partially sequenced by collisional
fragmentation. The fragmented peptide was found to
represent the tryptic fragment VDSLLENLEK, ie amino acids
207–216 (C2 protein numbering). Four other peptides were
partially sequenced and all of them matched the human
C1/C2 hnRNP sequence. The theoretical masses of C1 and
C2 are 32.0 and 33.3 kDa, respectively. The difference
between the two sequences is a 13-amino-acid insert in C2
between positions 107 and 108 of C1. The presence of a
specific tryptic fragment in the MALDI-TOF peptide-mass
map from the higher-molecular-mass spot containing a 13-
amino-acid insert that was not present in the lower-molecular-
mass spot, further demonstrated that the two components
represented the two isoforms of the C class of hnRNPs.
The patient whose case prompted us to investigate the
specificities of these antibodies was a 72-year-old man who
had arthralgias and oligoarthritis but did not fulfill the criteria for
rheumatoid arthritis and did not have dermatological
complaints. The reactivity of various patient groups to the
C1/C2 hnRNP autoantigens was subsequently tested by
immunoblotting of HeLa-cell nuclear extracts. Of 59 patients
with rheumatoid arthritis, 19 with polymyositis, 33 with
scleroderma, and 10 with psoriatic arthritis, none had IgG
antibodies reacting with the two bands. Of sera from 139
consecutive patients who had moderately to strongly positive
speckled ANA patterns shown by indirect immunofluorescence
on HEp-2 cells, only two reacted with the C1/C2 hnRNP
bands in immunoblotting. One of these was from a young
woman (22 years old) whose complaints of muscle tenderness
were not explained by objective findings or abnormal laboratory
test results. The third patient that we identified through ANA
screening followed by immunoblotting was a 54-year-old male
who was being treated with methotrexate for long-standing
polymyositis in addition to psoriasis and possible osteoporosis. 
Discussion: The results confirm the existence of anti-C1/C2
antibodies in some patients with speckled ANAs. The antigens
were identified through the use of biochemical methods using
high-resolution separation techniques combined with mass-
spectrometry peptide mapping and database searches. As a
general approach, this is a powerful way to identify new
antigens using small amounts of material without the need for
conventional protein sequencing. The approach does require,
however, that the proteins can be found in databases, that they
are not extensively post-translationally modified, that they can
be digested enzymatically, and that they can be isolated in
appropriately pure form by the separation technique used.
It is not known at present if the C1/C2 antibodies may have
pathogenic relevance and/or relate to specific diagnoses or
subsets within the group of connective-tissue diseases. It does
appear that the reactivity is quite rare among ANA-positive
patients, and therefore many patients will have to be examined
to determine these issues. The fact that the antibodies to the
C1/C2 hnRNPs are revealed by indirect immunofluorescence
would indicate that the epitopes are accessible in intact, fixed
HEp-2 cells and thus probably reside outside the nucleic-acid-
binding domains that would be expected to be covered by RNA.http://arthritis-research.com/content/2/5/407
rheumatic diseases. The protein components of hnRNP are
the most abundant nonhistone proteins of the cell nucleus
and are classified roughly on the basis of their molecular
masses into at least 21 protein groups (A through U).
Autoantibodies to the A2, B1, and B2 proteins of hnRNP
found in some patients may be markers of several overlap
syndromes [2]. However, ANAs with specificity for these
proteins as well as for the D protein and the I protein also
appear to occur in many distinct connective-tissue dis-
eases, although epitope specificities may differ [3,8].
Despite the discovery of the A, B, and R hnRNP ANA
specificities in patients [2,9,10], antibodies against the C
component of hnRNP (consisting of the C1 and C2 pro-
teins) have to our knowledge so far been described in only
one case [4]. The identification in this study was based on
the colocalization of patient immunoreactivity on immuno-
blots of nuclear extracts with the band developed with a
monoclonal anti-C1/C2 antibody. In the present study, we
identify the C1/C2 specificity of circulating ANAs in three
patients by high-resolution separation techniques (2D gel
electrophoresis) combined with the assignment of protein
identities by mass-spectrometric (MS and tandem MS)
peptide mapping. This protein was also found to be the
target of the ANA found in the patient described earlier [4].
Materials and methods
Reagents
Trifluoroacetic acid was from Fluka (Buchs, Switzerland),
HPLC-grade water and acetonitrile from Merck (Darmstadt,
Germany), sequencing-grade trypsin from Promega
(Madison, WI, USA). The bicinchonic acid assay for protein
was from Pierce (Rockford, IL, USA). All other chemicals
were of analytical grade from Sigma Chemical Co (St Louis,
MO, USA).
Cells and antibodies
HeLa-cell nuclei were obtained from 4C (Mons, Belgium).
Cultured carcinoma (HEp-2)-cell slides were from
Immunoconcepts, Inc (Sacramento, CA, USA). Fluores-
cein- and alkaline-phosphatase-labeled rabbit anti-human
IgG antibodies (F0202 and D0336, respectively) were
from Dako (Glostrup, Denmark). A patient serum sample
previously described as containing antibodies reacting
with C1/C2 hnRNP [4] was generously provided by Dr J
Vencovský, Prague.
Indirect immunofluorescence
Patient sera were screened for ANAs by indirect immuno-
fluorescence microscopy on slides of acetone-fixed HEp-2
cells using a cutoff dilution of 1:160 for the patient sera.
Preparation of HeLa-cell nuclear extracts
To establish the best conditions for extracting the anti-
gens, the nuclear material was subjected to five different
procedures: high-salt extraction using either 0.5 M NaCl
or 6 M guanidinium hydrochloride in 125 mM Tris/HCl, pH
6.8 (sonicated for 3×5s  a t  2 00 0 0H z  o n  ice); detergent
extraction in 125 mM Tris/HCl, pH 6.8, with 5% b-octyl
glucoside or with 2.5% Triton X-100, using sonication as
above; or extraction with 2.5% SDS for 10 min on ice after
mixing. All samples were subsequently centrifuged at
16000 × g for 5 min and the supernatants were then ana-
lyzed by gel electrophoresis and immunoblotting (high-salt
samples after being diluted 10 times in water). Extracts
were either stored at –80°C or processed immediately for
1D or 2D gel electrophoresis or for reversed-phase HPLC.
Reversed-phase HPLC
HeLa-cell nuclear extracts were separated by reversed-
phase HPLC on an analytical C4 column (4.6 × 250 mm,
300 Å, 5 mm particle size) from Vydac (Hesperia, CA, USA)
using an Äkta chromatography system (Pharmacia, Lund,
Sweden). The column was eluted with a 50-min gradient of
0–70% acetonitrile in 0.1% aqueous trifluoroacetic acid at
1 ml/min with monitoring at 210 and 280 nm. Fractions of
1 ml were collected. Prior to testing for reactivity with
patient sera, the collected fractions were dried down in a
Savant SpeedVac (Farmingdale, NY, USA) and resolubi-
lized in 100 ml water. Dots of 2 ml of these fractions were
subsequently placed on nitrocellulose, dried, and devel-
oped with patient sera as detailed below.
One- and 2D gel electrophoresis and immunoblotting
SDS–PAGE was performed in 10% precast gels from
Novex (San Diego, CA, USA). Samples were solubilized at
a protein concentration of 1–2 mg/ml by boiling 20-ml
aliquots for 3 min in the presence of 2.5% (w/v) SDS and
25 mM dithiothreitol in 10 mM Tris/HCl, pH 8, 10% (v/v)
glycerol. The sample buffer also contained 50 mg/ml
Pyronin G as a marker. The electrophoresis running buffer
was 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3
(Novex), and separation took place at 120 V for 1–2 h until
the marker reached 1 cm from the bottom edge of the gel.
Two-dimensional electrophoresis was used to analyze
crude HeLa-cell nuclear extracts and HPLC-purified sub-
fractions of the extracts. Prior to isoelectric focusing,
samples were solubilized at a protein concentration of
approximately 1 mg/ml in 1.5% (v/v) Ampholine 3.5–9.5
(Pharmacia), 0.75% (w/v) SDS, 12 mM dithiothreitol, 2 M
urea, 1% CHAPS (3-[{3-cholamidopropyl}-dimethylammo-
nio]-1-propane sulfonate), and an aliquot of bromphenol
blue. Isoelectric focusing of 17-ml samples took place in
1-mm × 130-mm tube gels (4% acrylamide [C = 2.7%]
containing 9 M urea, 1% [w/v] CHAPS, and 0.5% [v/v]
Nonidet P40). The first-dimension isoelectric focusing was
performed at 400 V for 17–18 h and then at 800 V for 1 h.
After the isoelectric focusing, the tube gels were extruded
and placed on top of a large (13 × 13 cm) 11% polyacry-
lamide gel (C = 2.7%) prepared in a Protean Cell (BioRad,
Hercules, CA, USA). After equilibration for about 1 min in
the presence of 500 ml transfer buffer (6.25 mM Tris/HCl,pH 6.8, 10% [v/v] glycerol, 2% [w/v] SDS, 200 mM
dithiothreitol, and an aliquot of bromophenol blue), the
second-dimension SDS–PAGE took place at a constant
15 W/gel for 4–5 h. One- and 2D gels were either silver-
stained using a modified protocol of Heukeshoven and
Dernick [11], in which glutaraldehyde had been left out, or
they were electroblotted for 1 h at 1 mA/cm2 onto nitrocel-
lulose of pore size 0.2 mm in a semidry electroblotting cell,
according to standard procedures. Blots were blocked
with non-ionic detergent (2% Tween 20) for 5 min and
developed with patient sera (diluted 1:100 unless other-
wise noted) and alkaline-phosphatase-labeled anti-human
IgG antibodies at 1:2000 using Nitroblue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate for the color reaction
as described elsewhere [12].
In-gel digestion of proteins separated by gel
electrophoresis
In-gel digestion was performed as described previously
[6]. The excised gel plugs were washed in 50 mM
NH4HCO3/acetonitrile (60/40) and dried by vacuum cen-
trifugation. The trypsin (sequencing grade), dissolved in
50 mM NH4HCO3 at 12 ng/ml, was added to the dry gel
pieces and incubated on ice for 1 h for reswelling. The
supernatant was removed, 60 ml digestion buffer was
added, and the digestion was continued at 37oC for
4–18 h. The peptide mixture was analyzed directly by
MALDI-MS without extraction by depositing a 0.8-ml 1:1
mixture of analyte solution in 2% trifluoroacetic acid and
matrix solution (15–20 g/l a-cyano-4-hydroxycinnamic
acid in 70% acetonitrile) directly on the MALDI target.
In other cases, the samples were desalted and concen-
trated as described elsewhere [13], and for analysis by
MALDI-MS, the peptides were eluted with 0.5 ml matrix
solution (15–20 g/l of a-cyano-4-hydroxycinnamic acid in
70% acetonitrile) and deposited directly on the MALDI
target. For tandem MS, the peptides on the column were
eluted with 1.5 ml 50% methanol/49% H2O/1% formic
acid directly into the nanoelectrospray needle.
Peptide-mass mapping by MALDI-MS
A Bruker REFLEX model MALDI-TOF mass spectrometer
(Bruker-Franzen Analytik GmbH, Bremen, Germany)
equipped with the Scout source and variable detector
bias gating was used in positive-ion reflector mode for
mass analysis of peptide mixtures (peptide-mass
mapping). The ion acceleration voltage was 20 kV.
ESI-Q-TOF MS
Tandem MS of peptides generated by in-gel digestion was
performed on a nano-ESI-Q-TOF mass spectrometer
(Micromass, Manchester, UK). Ions were produced in an
atmospheric pressure ionization (API)/ESI ion source at
40°C. The flow rate of the drying gas was 50 l/h. A poten-
tial of 1 kV was applied to the precoated borosilicate
nanoelectrospray needles (Protana A/S, Odense,
Denmark), and a stable flow rate (10–30 nl/min) was pro-
duced with a nitrogen back-pressure of 0–5 psi
(0–34.5 kPa). The cone voltage was 50 V. A quadrupole
analyzer was used to select the precursor ion for fragmen-
tation in the hexapole collision cell. The collision gas was
argon at a pressure of 6 × 10–5 mbar (6 × 10–3 Pa) and
the collision voltage was 20–25 V. Product ions were ana-
lyzed using an orthogonal TOF analyzer. Data were
processed with a Mass Lynx Windows NT-based program.
Protein identification
Protein identification by peptide-mass fingerprinting was
performed by searching the peptide masses in a compre-
hensive non-redundant protein sequence database
(NRDB; European Bioinformatics Institute, Hinxton, UK)
containing approximately 420000 protein sequences,
using the database search program PepSea (Protana,
Odense, Denmark). The peptide-mass maps and the
protein identifications were evaluated as described in [6].
The partial amino acid sequences of the peptides gener-
ated by tandem MS together with the associated masses
were used to construct the peptide sequence tags [7] that
were used to identify the proteins in the NRDB.
Results
Indirect immunofluorescence on HEp-2 cells
The starting point for the investigation into the specificity of
the antibodies in the present study was the observation of
an unusual staining pattern in a patient serum being tested
for IgG reactivity on HEp-2 cells. A strong nuclear staining
pattern (titer >1280) with very even-sized, coarse speckles
and no staining of nucleoli was observed (Fig. 1). This
staining pattern did not resemble the well-known variably
sized spliceosomal speckled pattern seen with antibodies
to Sm/U1RNP or the fine speckled pattern characteristic of
SSA/SSB-antibody-positive sera. In accordance with this,
the patient had none of these antibody specificities when
tested by specific assays (data not shown).
Determination of antigen molecular mass in HeLa-cell
nuclear extracts
The IgG reactivity of the serum shown in Fig. 1 was tested
on an SDS–PAGE-separated nuclear extract from HeLa
cells as shown in Fig. 2. A double band in the Mr
40000–42000 range and a high-molecular-mass band
(around 200000) were observed as the sole reactivities of
this particular patient (Fig. 2, lane 2). Sera from two other
patients, with a similar atypical ANA-staining pattern, also
stained components of this doublet in immunoblotting
(Fig. 2, lanes 3 and 4). The reactivity strongly resembled
that of the patient originally described by Stanek et al [4]
(Fig. 2, lane 5). The two different, more weakly reacting,
sera appear to react preferentially with either the lower
(lane 3) or the higher (lane 4) band, respectively. There
was no reactivity with a normal serum (lane 1, Fig. 2). The
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ionic detergent extracts of nuclei but appeared to be
extracted to the highest degree in the b-octyl glucoside
extracts (data not shown).
Enrichment of antigen preparation
After verification by immunoblotting that antibody reactivity
was present in crude HeLa-cell nuclear extracts obtained
by treatment with b-octyl glucoside (Fig. 2), the antigen
was enriched by fractionating the extract by reversed-
phase HPLC on a C4 column. Two of the collected frac-
tions contained material with a molecular mass around
40000 that was reactive with the patient antibody as
judged by SDS–PAGE immunoblotting (data not shown).
Micropreparative separation of antigens
The contents of the crude nuclear extract obtained after
b-octyl glucoside treatment were separated by 2D gel
electrophoresis into several hundred components
(Fig. 3a). However, the patient antibodies only reacted
with two components in the mixture on immunoblots of the
2D separation (Fig. 3b). The two components appeared to
be of approximately the same isoelectric points, but they
differed in molecular mass by approximately 2000. The
purified fractions from the C4 reversed-phase HPLC sepa-
ration gave a less complicated 2D separation pattern
(Fig. 3c), in which the two reactive spots (encircled) could
be clearly identified and were positive on immunoblotting
with patient serum (Fig. 3d). These two spots were
excised for individual characterization.
Protein identification
MALDI-TOF peptide-mass mapping was performed on the
tryptic peptide mixture generated by in-gel digestion of the
two components after excision from 2D gels in two indepen-
dent experiments. The database search compared the
detected peptide masses with the theoretical tryptic peptide
masses of the protein sequences present in the database.
This approach in both sets of experiments suggested that
the two proteins were hnRNPs C1/C2 (Swissprot accession
number P07910), a conclusion suggested by the matching
of 8 of 27 peptide masses entered (data not shown). The
low number of matched peptides relative to the number of
peptides included in the search, together with the small dif-
ference in the number of matching peptides to the next hit in
the database (three peptides), make this identification only
tentative. Therefore, the identity of the proteins was further
confirmed by tandem MS using an ESI-Q-TOF instrument.
One peptide carrying two positive charges (m/z 580.32 Da)
corresponding to a peptide mass of 1158.7 Da was
selected as a precursor ion and fragmented in the collision
http://arthritis-research.com/content/2/5/407
Figure 1
Indirect immunofluorescence pattern of anti-C1/C2-positive patient
serum on HEp-2 cells. Cells were incubated with diluted patient serum
(1:160), and bound IgG was detected by fluorescence microscopy
after incubation with fluoresceinylated rabbit anti-human IgG. Strongly
positive, very regular, coarse nuclear staining that spares nucleoli is
observed. Original magnification is 200×. Scale bar is 10 mm.
Figure 2
Immunoblotting using different patient sera (2–5) and a normal control
serum (1) diluted 1:100 on blots of HeLa-cell nuclear extracts
separated on SDS–PAGE. The serum examined in lane 2 is identical
to the one shown in Fig. 1, and the serum in lane 5 is a sample from
the original patient described by Stanek et al [4]. Developed with anti-
IgG antibodies. Molecular masses (×10–3) of standard proteins are
indicated on the left.cell. The fragment ion spectrum is illustrated in Fig. 4a. A
peptide sequence tag [7] consisting of a partial sequence
and its associated masses was constructed –
(632.36)LLSD(1060.70) – and was used to search the
NRDB. The database search subsequently unambiguously
identified the protein as human C1/C2 hnRNP (data not
shown). The fragmented peptide was found to represent the
tryptic fragment VDSLLENLEK, ie amino acids 207–216
(C2 protein numbering). Four other peptides were partially
sequenced, and all were found to match the human C1/C2
hnRNP sequence (data not shown). Several of the peptide
masses that were not matched to the sequence could be
matched to peptides derived from keratin and from autopro-
teolysis of trypsin (data not shown).
The theoretical masses of C1 and C2 are 32.0 and 33.3
kDa, respectively. The difference between the two
sequences is a 13-amino-acid insert in C2 between posi-
tions 107 and 108 of C1. The presence of a specific
tryptic fragment in the MALDI-TOF peptide-mass map from
the upper spot but not from the lower spot containing a 13-
amino-acid insert in the protein sequence (SAAEMYGSVT-
EHPSPSPLLSSSFDLDYDFQR) clearly demonstrates that
the two components in the gel represent the two isoforms
of the C-class of hnRNPS (Fig. 4b). The peptide-mass map
of C1 contains a peptide signal at m/z 2101.9 Da, corre-
sponding to the tryptic peptide without the 13-amino-acid
insert – SAAEMYGSSFDLDYDFQR.
Patients and clinical data
The patient whose case prompted us to investigate the
specificities of these antibodies was a 72-year-old man
with a speckled ANA titer of >1280, who had arthralgias
and oligoarthritis but did not fulfill the criteria for rheuma-
toid arthritis and did not have dermatological complaints.
The reactivity of sera from various patient groups towards
the C1/C2 hnRNP autoantigens was subsequently tested
by immunoblotting of HeLa-cell nuclear extracts. None of
59 patients with rheumatoid arthritis, 19 with polymyositis,
33 with scleroderma, and 10 with psoriatic arthritis had
IgG antibodies reacting with the two bands. Among 139
consecutive patients who had moderately to strongly posi-
tive speckled ANA patterns by indirect immunofluores-
cence on HEp-2 cells, only two additional patients had
sera that reacted with the C1/C2 hnRNP bands in
immunoblotting (Fig. 2, lanes 3 and 4). The serum of one of
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Figure 3
Isolation of antibody-reactive proteins by 2D gel electrophoresis and immunoblotting. (a) Two-dimensional gel electrophoresis of HeLa-cell nuclear
extract. Molecular-weight marker positions are indicated on the left. Isoelectric focusing was in the horizontal dimension with the anode on the left.
The gel is silver-stained. (b) Immunoblot from a separation similar to the one shown in (a), developed with the patient serum diluted 1:200. (c)
Two-dimensional electrophoresis of a fraction of the nuclear extract purified by reversed-phase HPLC. (d) The immunoblot of the separation in (c),
developed with a 1:200 dilution of patient serum. The two prominent spots marked with a circle in (c) were cut out separately and analyzed by MS
after in-gel trypsin digestion.these patients reacted preferentially with the C1 hnRNP,
and that of the other reacted with the C2 hnRNP and thus
may be specific for the C2 insert. One patient was a young
woman (22 years old) with complaints of muscle tender-
ness but without objective findings or other abnormal labo-
ratory test findings, whose sera showed speckled ANAs,
with a titer of >1280. A third patient whose case we identi-
fied through ANA screening followed by immunoblotting
was a 54-year-old man, whose sera also showed speckled
ANAs, with a titer of >1280. This man was receiving
methotrexate and had long-standing polymyositis in addi-
tion to psoriasis and possible osteoporosis.
Discussion
Although the prototype serum found in our study strongly
matched the reactivity of the serum from the report by
Stanek et al [4] with respect to the singular staining
pattern shown in Fig. 1, it probably would not be recog-
nized as such in routine diagnostic laboratory tests.
The present study confirms the existence of anti-C1/C2
antibodies in some patients with speckled ANAs. The anti-
gens were identified through the use of biochemical
methods using high-resolution separation techniques
combined with mass-spectrometry peptide mapping and
database searches. As a general approach, this is a pow-
erful way to identify new antigens using small amounts of
material without the need for conventional protein
sequencing and consequently with no problems related to
blocked N-termini. The approach does require, however,
that the proteins can be found in databases, that they are
not extensively post-translationally modified, that they can
be digested enzymatically, and that they can be isolated in
appropriately pure form by the separation technique used.
The C1 and C2 proteins are identical except for an insert
of 13 amino acids after serine 107 in the 303-amino-acid-
containing C2 protein [14,15]. The presence of this insert
accounts for the separation of the C1 and C2 proteins by
SDS–PAGE. Like other hnRNPs, they contain consensus
sequence RNA-binding domains and nuclear localization
signals [15]. The C1/C2 proteins form anisotropic
([C1]3[C2]1) tetramers that bind strongly but apparently
nonspecifically to RNA and probably form a basic struc-
tural unit in pre-mRNA-processing and RNA-packaging
complexes [14,16–18]. Together with the A and B groups
of hnRNPs, they constitute the core proteins of the 40S
hnRNP particles [19]. C1 and C2 are phosphorylated,
contain unusually acidic C-terminal domains, and, accord-
ingly, are the most acidic of the hnRNPs.
It is not known at present if the C1/C2 antibodies are path-
ogenically relevant and/or relate to specific diagnoses or
subsets within the group of connective-tissue diseases.
Although ELISA with native antigen may increase the
number of positive findings, reactivity does seem to be quite
rare among ANA-positive patients. Therefore, clarification of
these issues would require the study of many patients.
Autoantibodies to many of the core proteins of the hnRNP
complex have now been described, including the A1,
A2/RA33, A3, B1, and B2 proteins as well as D/AUF-1 and,
recently, also the hnRNP R protein [2,3,9,10]. These pro-
teins are primarily involved in packaging and processing of
pre-mRNA and in the regulation of alternative splicing.
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Figure 4
Identification of C1/C2 hnRNPs by MS and by tandem MS
sequencing. (a) Collision-induced dissociation spectrum of a doubly
charged ion at m/z 580.32 Da corresponding to the sequence
207–216 (VDSLLENLEK) of the C2 hnRNP. The Y ion signal series is
shown together with the deduced sequence giving the peptide
sequence tag (632.36)LLSD(1060.70). (b) Two sections of the
MALDI-MS peptide-mass maps showing the difference between the
upper (C2) hnRNP and the lower (C1) hnRNP spots excised from 2D
gels (cf Fig. 3c). The signal at m/z 3433.6 Da detected in the trypsin-
digested material from the upper spot could be identified as the tryptic
peptide that includes the 13-amino-acid insert in C2 hnRNP (illustrated
in the figure). Only the corresponding peptide without the insert could
be detected (at m/z 2101.9 Da) in the peptide-mass map from the
lower spot. Signals derived by autoproteolysis of trypsin are marked
with stars.They may also be involved in RNA transport between the
nucleus and the cytoplasm. ANAs directed against these
proteins do not give clear-cut ANA reactivity on commonly
used ANA substrates such as HEp-2 cells [20,21]. This is
probably because the antibodies specifically target RNA-
binding domains that are shielded by bound RNA in intact
cells. The fact that these antibodies often appear together
with other ANAs in systemic lupus erythematosus, in
mixed connective-tissue diseases, and in adult and juve-
nile rheumatoid arthritis has made it difficult to study their
presence except by immunoblotting of extracts treated
with DNase and RNase to remove nucleic acids. The fact
that antibodies to the C1/C2 hnRNPs are revealed by indi-
rect immunofluorescence indicates that the epitopes are
accessible in intact, fixed HEp-2 cells and thus are proba-
bly outside nucleic-acid-binding domains that would be
expected to be covered by RNA.
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